Role of Glucagon-Like Peptide-1 Analogue Versus Amylin as an Adjuvant Therapy in Type 1 Diabetes in a Closed Loop Setting With ePID Algorithm
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Aims/Hypothesis: Postprandial hyperglycemia due to paradoxical hyperglucagonemia is a major challenge of diabetes treatment despite the use of the artificial pancreas. We postulated that adjunctive therapy with pramlintide or exenatide would attenuate hyperglycemia in the postprandial phase through glucagon suppression, thereby optimizing the functioning of the closed-loop (CL) system. Methods: Subjects with type 1 diabetes (T1DM) on insulin pump therapy were recruited to participate in a 27-hour hospitalized admission on 3 occasions (2-4 weeks apart) and placed on the insulin delivery via CL system in random order to receive (1) insulin alone (control), (2) exenatide 2.5 µg + insulin, (3) pramlintide 30 µg + insulin. Medications were given prior to lunch and dinner, which was a standardized meal of 60 grams of carbohydrates. Insulin delivery was as per the ePID algorithm via the Medtronic CL system and continuous subcutaneous glucose monitoring via Medtronic Sof-sensors. Ten subjects age 23 ± 1 years with a HbA1c of 7.29 ± 0.3% (56 ± 1 mmol/mol) and duration of T1DM 10.6 ± 2.0 years participated in the 3-part study. Results: Exenatide was found to be significantly better in attenuating postprandial hyperglycemia as compared to insulin monotherapy ( P < .03) and pramlintide ( P > .05). Glucagon suppression was statistically significant with exenatide ( P < .03) as compared to pramlintide. Insulin requirements were lower with adjunctive therapy, but statistically insignificant. Conclusions/Interpretations: Insulin monotherapy results in postprandial hyperglycemia in T1DM in the CL setting and adjunctive therapy with exenatide reduces postprandial hyperglycemia effectively and should be considered as adjunctive therapy in T1DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kovatchev, B., Cobelli, C., Renard, E., Anderson, S., Breton, M., Patek, S., Clarke, W., Bruttomesso, D., Maran, A., Costa, S., et al. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400611 · Cited by 200
Kielgast, U., Holst, J. J., & Madsbad, S. (2011) · Diabetes · doi:10.2337/db10-1790 · Cited by 137
Efficacy and harms of the hypoglycemic agent pramlintide in diabetes mellitus
Lee, N. J., Norris, S. L., & Thakurta, S. (2010) · The Annals of Family Medicine · doi:10.1370/afm.1174 · Cited by 39
Cited by
Schwartz, S. S., Epstein, S., Corkey, B. E., Grant, S. F. A., Gavin, J. R., & Aguilar, R. B. (2016) · Diabetes Care · doi:10.2337/dc15-1585 · Cited by 329
Coming of age: the artificial pancreas for type 1 diabetes
Thabit, H., & Hovorka, R. (2016) · Diabetologia · doi:10.1007/s00125-016-4022-4 · Cited by 223
“In another study, the use of either pramlintide or exenatide during closed-loop insulin delivery were compared with closed-loop insulin delivery alone, over 27 h [90].”
MethodISPAD Clinical Practice Consensus Guidelines 2018: diabetes technologies
Sherr, J. L., Tauschmann, M., Battelino, T., de Bock, M., Forlenza, G., Roman, R., Hood, K. K., & Maahs, D. M. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12731 · Cited by 197
Gingras, V., Taleb, N., Roy‐Fleming, A., Legault, L., & Rabasa‐Lhoret, R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13052 · Cited by 113
“An attenuation in postprandial BG and glucagon levels was significant with exenatide but not with amylin in 10 patients over 27 hours.(110) Pramlintide was better tolerated than exenatide in terms of gastrointestinal side effects (4 patients in the exenatide versus one in the amylin group), but no hypoglycaemia episod…”
Efficacy of hybrid closed-loop system in adults with type 1 diabetes and gastroparesis
Kaur, H., Schneider, N., Pyle, L., Campbell, K., Akturk, H. K., & Shah, V. N. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0254 · Cited by 24
Metadata
- Authors
- Renukuntla, V. S., Ramchandani, N., Trast, J., Cantwell, M., & Heptulla, R. A.
- Venue
- Journal of Diabetes Science and Technology
- Publisher
- SAGE Publications
- Published
- 2014-07-16
- Volume
- 8
- Issue
- 5
- Pages
- 1011-1017
- ISSN
- 1932-2968 (ISSN-L)
- OpenAlex
- W2141856790
- Cited by
- 56
- References
- 3
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of Glucagon-Like Peptide-1 Analogue Versus Amylin as an Adjuvant Therapy in Type 1 Diabetes in a Closed Loop Setting With ePID Algorithm. https://app.cochat.ai/papers/10.1177/1932296814542153
- The paper
- Renukuntla, V. S., Ramchandani, N., Trast, J., Cantwell, M., & Heptulla, R. A. (2014). Role of Glucagon-Like Peptide-1 Analogue Versus Amylin as an Adjuvant Therapy in Type 1 Diabetes in a Closed Loop Setting With ePID Algorithm. Journal of Diabetes Science and Technology. https://doi.org/10.1177/1932296814542153
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.